Contrasting Larimar Therapeutics (NASDAQ:LRMR) and Altimmune (NASDAQ:ALT)

Altimmune (NASDAQ:ALT) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Volatility & Risk

Altimmune has a beta of -0.03, suggesting that its share price is 103% less volatile than the S&P 500. Comparatively, Larimar Therapeutics has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500.

Earnings and Valuation

This table compares Altimmune and Larimar Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$20,000.00	20,894.09	-$95.06 million	($1.07)	-3.74
Larimar Therapeutics	N/A	N/A	-$80.60 million	($1.93)	-2.00

Larimar Therapeutics has lower revenue, but higher earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

78.1% of Altimmune shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 4.4% of Altimmune shares are held by insiders. Comparatively, 4.5% of Larimar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Altimmune and Larimar Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Altimmune	-419,575.00%	-54.79%	-47.59%
Larimar Therapeutics	N/A	-91.83%	-74.60%

Analyst Recommendations

This is a summary of current recommendations for Altimmune and Larimar Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	2	1	7	0	2.50
Larimar Therapeutics	1	0	8	0	2.78

Altimmune currently has a consensus price target of $16.83, suggesting a potential upside of 320.31%. Larimar Therapeutics has a consensus price target of $16.71, suggesting a potential upside of 332.90%. Given Larimar Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Larimar Therapeutics is more favorable than Altimmune.

Summary

Larimar Therapeutics beats Altimmune on 9 of the 13 factors compared between the two stocks.

About Altimmune

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

About Larimar Therapeutics

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.